Physician profile
John D Ramirez
NPI 1649266222
$2,398.09
in general payments reported to CMS, 2019-2025
20 companies · $1,459 in 2025
The $1,459 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2022: $204 · 2023: $40.75 · 2025: $1,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,276 · Food and Beverage: $206 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,276.16 |
| Food and Beverage | $205.86 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,479.67 | 2022-2025 | Linq II |
| United Therapeutics Corporation | $241.67 | 2019 | |
| Inspire Medical Systems, INC. | $131.50 | 2022 | |
| Pfizer INC. | $89.94 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $49.55 | 2019 | |
| Alnylam Pharmaceuticals INC. | $47.53 | 2019 | |
| Amgen INC. | $40.91 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.93 | 2019 | |
| Medtronic Vascular, INC. | $38.95 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.23 | 2019 | |
| Abbott Laboratories | $27.91 | 2022 | |
| Cvrx, INC. | $23.49 | 2023 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $22.72 | 2019 | |
| Edwards Lifesciences Corporation | $22.31 | 2019 | |
| Amarin Pharma, INC. | $22.01 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $20.16 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.67 | 2019 | |
| Philips North America LLC | $15.87 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.69 | 2019 | |
| Gilead Sciences, INC. | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.